KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Shows Durable 5-Year Survival Benefit Over Chemotherapy in Advanced Endometrial Carcinoma Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced updated five-year follow-up data from the pivotal Phase…
Genmab Reports Promising New Data Showing Rina-S® Demonstrates Strong Anti-Tumor Activity in Advanced Endometrial Cancer Genmab A/S (Nasdaq: GMAB) announced new and encouraging results from its Phase 1/2 RAINFOL™-01 clinical trial evaluating rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha…
Researchers at General Atomics (GA) are playing a pivotal role in addressing one of the most complex and persistent challenges in the pursuit of fusion energy — sustaining and controlling the high-energy fuel that powers fusion reactions. In a landmark…
The U.S. public sector is undergoing a sweeping transformation in how it envisions, builds, and operates its digital workplaces. A new research report by Information Services Group (ISG) (Nasdaq: III), a global AI-focused technology research and advisory firm, reveals that…
Evvy, the world’s leading platform leveraging the vaginal microbiome to improve women’s health outcomes, today announced record growth and compelling new data demonstrating the transformative impact of its platform. Evvy now serves over 75,000 patients and partners with more than…
EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced updated long-term results from the global Phase 3 MANEUVER trial, evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor, for the treatment…
Water- en Energiebedrijf Aruba N.V. (WEB) and Seven Seas Water Group, a leading multinational provider of Water-as-a-Service® (WaaS®) solutions, have officially broken ground on a new state-of-the-art seawater reverse osmosis (SWRO) desalination plant in Aruba. The project marks a major…
Diorasis Therapeutics, a biotechnology company pioneering durable gene therapies for glaucoma and other ophthalmic diseases, today announced the appointment of Dimitri Azar, MD, MBA, AM (hon.), DHL (hon.), to its Board of Directors. Dr. Azar is a globally recognized leader…
LGC Group, a global leader in life sciences, diagnostics, and analytical solutions, has officially opened its new £20 million National Laboratories facility in Guildford, marking a significant investment in the UK’s scientific infrastructure. The facility reinforces the nation’s leadership in…
Life Sciences BC has revealed the companies and mentors selected for its 2026 Investor Readiness Program (IRP), a six-month initiative designed to help emerging life sciences ventures in British Columbia attract investment, refine their business strategies, and accelerate growth. Now…